Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting Mpro and Ameliorates Pulmonary Inflammation
The coronavirus disease 2019 (COVID-19) has spread widely around the world and has seriously affected the human health of tens of millions of people. In view of lacking anti-virus drugs target to SARS-CoV-2, there is an urgent need to develop effective new drugs. In this study, we reported our disco...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2021-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_ccc497287b224ef5ae9a0e72e8cc8800 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Ting Xiao |e author |
| 700 | 1 | 0 | |a Ting Xiao |e author |
| 700 | 1 | 0 | |a Mengqi Cui |e author |
| 700 | 1 | 0 | |a Mengqi Cui |e author |
| 700 | 1 | 0 | |a Caijuan Zheng |e author |
| 700 | 1 | 0 | |a Ming Wang |e author |
| 700 | 1 | 0 | |a Ronghao Sun |e author |
| 700 | 1 | 0 | |a Dandi Gao |e author |
| 700 | 1 | 0 | |a Dandi Gao |e author |
| 700 | 1 | 0 | |a Jiali Bao |e author |
| 700 | 1 | 0 | |a Jiali Bao |e author |
| 700 | 1 | 0 | |a Shanfa Ren |e author |
| 700 | 1 | 0 | |a Shanfa Ren |e author |
| 700 | 1 | 0 | |a Bo Yang |e author |
| 700 | 1 | 0 | |a Jianping Lin |e author |
| 700 | 1 | 0 | |a Xiaoping Li |e author |
| 700 | 1 | 0 | |a Dongmei Li |e author |
| 700 | 1 | 0 | |a Cheng Yang |e author |
| 700 | 1 | 0 | |a Cheng Yang |e author |
| 700 | 1 | 0 | |a Honggang Zhou |e author |
| 700 | 1 | 0 | |a Honggang Zhou |e author |
| 245 | 0 | 0 | |a Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting Mpro and Ameliorates Pulmonary Inflammation |
| 260 | |b Frontiers Media S.A., |c 2021-06-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2021.669642 | ||
| 520 | |a The coronavirus disease 2019 (COVID-19) has spread widely around the world and has seriously affected the human health of tens of millions of people. In view of lacking anti-virus drugs target to SARS-CoV-2, there is an urgent need to develop effective new drugs. In this study, we reported our discovery of SARS-CoV-2 Mpro inhibitors. We selected 15 natural compounds, including 7 flavonoids, 3 coumarins, 2 terpenoids, one henolic, one aldehyde and one steroid compound for molecular docking and enzymatic screening. Myricetin were identified to have potent inhibit activity with IC50 3.684 ± 0.076 μM in the enzyme assay. The binding pose of Myricetin with SARS-CoV-2 Mpro was identified using molecular docking method. In the binding pocket of SARS-CoV-2 Mpro, the chromone ring of Myricetin interacts with His41 through π-π stacking, and the 3'-, 4'- and 7-hydroxyl of Myricetin interact with Phe140, Glu166and Asp187 through hydrogen bonds. Significantly, our results showed that Myricetin has potent effect on bleomycin-induced pulmonary inflammation by inhibiting the infiltration of inflammatory cells and the secretion of inflammatory cytokines IL-6, IL-1α, TNF-α and IFN-γ. Overall, Myricetin may be a potential drug for anti-virus and symptomatic treatment of COVID-19. | ||
| 546 | |a EN | ||
| 690 | |a COVID-19 | ||
| 690 | |a SARS-CoV-2 | ||
| 690 | |a 3CLpro (Mpro) | ||
| 690 | |a myricetin | ||
| 690 | |a pulmonary inflammation | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 12 (2021) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2021.669642/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/ccc497287b224ef5ae9a0e72e8cc8800 |z Connect to this object online. |